title: Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits.
authors: K Y
authors: KY
authors: Thong
authors: R E J
authors: RE
authors: Ryder
authors: M L
authors: ML
authors: Cull
authors: C
authors: C
authors: Walton
mesh_terms: D001334:Automobile Driving; D001786:Blood Glucose / Q000187:drug effects; D018795:Device Approval / Q000331:legislation & jurisprudence; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D000077270:Exenatide; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000819:agonists* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007003:Hypoglycemia / Q000150:complications; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008004:Licensure; D000069450:Liraglutide; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000627:therapeutic use*; D006113:United Kingdom; D014688:Venoms / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D010455:Peptides; D014688:Venoms; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1; D000077270:Exenatide